The Filing Desk

Cytek Biosciences vs 10x Genomics

Cytek Biosciences CTKB · 10x Genomics TXG · Life Sciences Tools & Services

10x Genomics reported revenue of $643 million in fiscal 2025, 3.2 times Cytek Biosciences' $202 million in fiscal 2025. Cytek Biosciences' revenue grew 0.5% in its latest year, and 10x Genomics' grew 5.2%. Cytek Biosciences had an operating margin of -20.0%, against -9.5% at 10x Genomics. Free cash flow was −$9 million at Cytek Biosciences and $130 million at 10x Genomics.

Side by side

Cytek Biosciences10x Genomics
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$202M$643M
Revenue growth0.5%5.2%
Revenue growth a year, last 5 years210.3%16.6%
Gross margin51.8%69.0%
Operating margin−20.0%−9.5%
Net margin−33.0%−6.8%
Free cash flow−$9M$130M
Free cash flow margin−4.3%20.2%
Return on capital—−16.3%
Net debt to EBITDA——
Dividends and buybacks$15M$0M
Change in diluted share count−2.2%3.6%
Last close$5.84$58.19
P/E at the last close——
Insider trades, last 12 months—sold $18.8 million
Piotroski F-score—5 of 9
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Cytek Biosciences10x Genomics
Operating margin
Percent of revenue
Cytek Biosciences10x Genomics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Cytek Biosciences10x Genomics

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Cytek Biosciences and 10x Genomics pages.